Susarla SK, Gupta M, Uttam KG, Palkar S, et al. Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study. Vaccine 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
PMID: 37661535